Literature DB >> 20182054

Caffeine as a protective factor in dementia and Alzheimer's disease.

Marjo H Eskelinen1, Miia Kivipelto.   

Abstract

Caffeine has well-known short-term stimulating effects on central nervous system, but the long-term impacts on cognition have been less clear. Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking. Thus, the putative protective effects of caffeine against dementia/AD are of great interest. Here, we discuss findings from the longitudinal epidemiological studies about caffeine/coffee/tea and dementia/AD/cognitive functioning with a special emphasis on our recent results from the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study. The findings of the previous studies are somewhat inconsistent, but most studies (3 out of 5) support coffee's favorable effects against cognitive decline, dementia or AD. In addition, two studies had combined coffee and tea drinking and indicated some positive effects on cognitive functioning. For tea drinking, protective effects against cognitive decline/dementia are still less evident. In the CAIDE study, coffee drinking of 3-5 cups per day at midlife was associated with a decreased risk of dementia/AD by about 65% at late-life. In conclusion, coffee drinking may be associated with a decreased risk of dementia/AD. This may be mediated by caffeine and/or other mechanisms like antioxidant capacity and increased insulin sensitivity. This finding might open possibilities for prevention or postponing the onset of dementia/AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182054     DOI: 10.3233/JAD-2010-1404

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  71 in total

1.  Caffeine Content Labeling: A Missed Opportunity for Promoting Personal and Public Health.

Authors:  Jon Kole; Anne Barnhill
Journal:  J Caffeine Res       Date:  2013-09

2.  Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Authors:  Kang-Woo Lee; Joo-Young Im; Jong-Min Woo; Hilary Grosso; Yoon-Seong Kim; Ana Clara Cristovao; Patricia K Sonsalla; David S Schuster; Marla M Jalbut; Jose R Fernandez; Michael Voronkov; Eunsung Junn; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 3.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

4.  Coffee consumption and incident dementia.

Authors:  Saira Saeed Mirza; Henning Tiemeier; Renée F A G de Bruijn; Albert Hofman; Oscar H Franco; Jessica Kiefte-de Jong; Peter J Koudstaal; M Arfan Ikram
Journal:  Eur J Epidemiol       Date:  2014-08-26       Impact factor: 8.082

Review 5.  Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  A J Carman; P A Dacks; R F Lane; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

6.  Adenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxiety.

Authors:  Gabriel S Chiu; Patrick T Darmody; John P Walsh; Morgan L Moon; Kristin A Kwakwa; Julie K Bray; Robert H McCusker; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2014-06-04       Impact factor: 7.217

7.  Caffeine impact on working memory-related network activation patterns in early stages of cognitive decline.

Authors:  Sven Haller; Marie-Louise Montandon; Cristelle Rodriguez; Dominik Moser; Simona Toma; Jeremy Hofmeister; Panteleimon Giannakopoulos
Journal:  Neuroradiology       Date:  2017-03-13       Impact factor: 2.804

8.  Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.

Authors:  Mahmoud L Soliman; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-15       Impact factor: 4.147

9.  Gene-environment interaction research and transgenic mouse models of Alzheimer's disease.

Authors:  L Chouliaras; A S R Sierksma; G Kenis; J Prickaerts; M A M Lemmens; I Brasnjevic; E L van Donkelaar; P Martinez-Martinez; M Losen; M H De Baets; N Kholod; F van Leeuwen; P R Hof; J van Os; H W M Steinbusch; D L A van den Hove; B P F Rutten
Journal:  Int J Alzheimers Dis       Date:  2010-10-05

10.  Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280.

Authors:  Frank J A Dennissen; Marta Anglada-Huguet; Astrid Sydow; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.